(Q34376884)

1 August 2017

title

Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor (English)

1 reference

1 August 2017

0 references

2

1 reference

1 August 2017

3

1 reference

1 August 2017

Katrina Weston-Green

1

0 references

publication date

1 December 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

27

1 reference

1 August 2017

issue

12

1 reference

1 August 2017

page(s)

1069-1080

1 reference

Atypical antipsychotics for aggression and psychosis in Alzheimer's disease

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Inpatient antipsychotic drug use in 1998, 1993, and 1989.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Atypical antipsychotics for nursing home patients: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Olanzapine in the management of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Body weight gain induced by antipsychotic drugs: mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

New-onset type-2 diabetes associated with atypical antipsychotic medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: Validation with olanzapine and ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Olanzapine affects locomotor activity and meal size in male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Preclinical models of antipsychotic drug-induced metabolic side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Clozapine-associated diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Central control of glucose homeostasis: the brain--endocrine pancreas axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Autonomic regulation of islet hormone secretion--implications for health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Brain control of insulin and glucagon secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

The gut-brain axis: a major glucoregulatory player

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Insulin reduces excitation in gastric-related neurons of the dorsal motor nucleus of the vagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Distribution of insulin receptor substrate-2 in brain areas involved in energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: new therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Diabetes, obesity, and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Neuroendocrinology of the pancreas; role of brain-gut axis in pancreatic secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Plasma glucose, non-esterified fatty acid and insulin concentrations in hypothalamic-hyperphagic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Consequences of ventromedial hypothalamic lesions upon insulin and glucagon secretion by subsequently isolated perfused pancreases in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Acute Hyperinsulinemia and Its Reversal by Vagotomy after Lesions of the Ventromedial Hypothalamus in Anesthetized Rats*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

CNS modulation of pancreatic endocrine function. Multiple modes of expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Acute intracarotid glucose injection towards the brain induces specific c-fos activation in hypothalamic nuclei: involvement of astrocytes in cerebral glucose-sensing in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Neuronal activation of brain vagal-regulatory pathways and upper gut enteric plexuses by insulin hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Rethinking the central causes of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Novel approaches to studying the role of innervation in the biology of pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Vagal control of digestion: modulation by central neural and peripheral endocrine factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Brainstem circuits regulating gastric function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Tumor necrosis factor-alpha, interleukin-1beta and nitric oxide induce calcium transients in distinct populations of cells cultured from the rat area postrema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Neuropeptide Y innervation of amygdaloid and hypothalamic neurons that project to the dorsal vagal complex in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Ghrelin-containing neuron in cerebral cortex and hypothalamus linked with the DVC of brainstem in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Hypothalamus-brain stem circuitry responsible for vagal efferent signaling to the pancreas evoked by hypoglycemia in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Half a century of antipsychotics and still a central role for dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Role of the cholinergic system in the pathology and treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Chronic phencyclidine (PCP)-induced modulation of muscarinic receptor mRNAs in rat brain: impact of antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Unusual suspect for antipsychotic-induced diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Effect of chlorpromazine on blood glucose and plasma insulin in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Localization of muscarinic m3 receptor protein and M3 receptor binding in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Muscarinic M(1), M(3) receptors function in the brainstem of streptozotocin induced diabetic rats: their role in insulin secretion from the pancreatic islets as a function of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Alterations in the muscarinic M1 and M3 receptor gene expression in the brain stem during pancreatic regeneration and insulin secretion in weanling rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Central Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Interactions between the central nervous system and pancreatic islet secretions: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Novel insights into the function of β-cell M3 muscarinic acetylcholine receptors: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

The versatility of the vagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

The vagus nerve, food intake and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Necessity of intracellular cyclic AMP in inducing gastric acid secretion via muscarinic M3 and cholecystokinin2 receptors on parietal cells in isolated mouse stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Beneficial Metabolic Effects Caused by Persistent Activation of β-Cell M3 Muscarinic Acetylcholine Receptors in Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Beneficial metabolic effects of M3 muscarinic acetylcholine receptor deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Ringing the dinner bell for insulin: muscarinic M3 receptor activity in the control of pancreatic beta cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Effects of muscarinic receptor type 3 knockout on mouse islet secretory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Critical metabolic roles of β-cell M3 muscarinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Hepatic muscarinic acetylcholine receptors are not critically involved in maintaining glucose homeostasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Regional binding of 4-diphenylacetoxy-N-methylpiperidine methobromide (4-DAMP) to muscarinic receptors in rat brain and comparative analysis of minimum energy conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Atypical antipsychotics and diabetic ketoacidosis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0115-5

Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat

21 January 2018

1 reference

12 December 2020

Intracerebroventricular injection of methylatropine suppresses insulin response to oral glucose load in rats

1 reference

12 December 2020

Towards a muscarinic hypothesis of schizophrenia.

1 reference

12 December 2020

Progress in the search for neuronal mechanisms coupling type 2 diabetes to obesity

1 reference

12 December 2020

International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

1 reference

12 December 2020

Comparison of insulin sensitivity, clearance, and secretion estimates using euglycemic and hyperglycemic clamps in children

1 reference

12 December 2020

Aggregation of insulin by chlorpromazine

1 reference

12 December 2020

The effect of atropine on the insulin release caused by oral and intravenous glucose in human subjects

1 reference

12 December 2020

An open-label study of the treatment efficacy of olanzapine for Tourette's disorder.

1 reference

12 December 2020

Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model

1 reference

12 December 2020

Clozapine versus other atypical antipsychotics for schizophrenia

1 reference

12 December 2020

Critical role of M3 muscarinic receptor in insulin secretion: implications for psychopharmacology

1 reference

12 December 2020

Oxotremorine-m potentiation of glucose-induced insulin release from rat islets involves M3 muscarinic receptors

1 reference

12 December 2020

Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects

1 reference

12 December 2020

Autoradiographic mapping of M3 muscarinic receptors in the rat brain

1 reference

12 December 2020

The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets

1 reference

12 December 2020

Plasma insulin and triglyceride levels after hypothalamic lesions in weanling rats.

1 reference

12 December 2020

Diabetes resolution following discontinuation of a second-generation antipsychotic

1 reference

12 December 2020

CNS modulation of pancreatic endocrine function : Multiple modes of expression

1 reference

12 December 2020

Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks.

1 reference

12 December 2020

1 reference

12 December 2020

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

1 reference

12 December 2020

Hypoglycemia induced changes in cholinergic receptor expression in the cerebellum of diabetic rats

1 reference

12 December 2020

Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone

1 reference

12 December 2020

10.1007/S40263-013-0115-5

Identifiers

DOI

1 reference

1 August 2017

1 reference